8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 25, 2013)

Filed July 25, 2013For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on July 25, 2013, to report its financial results for the second quarter ended June 30, 2013. The primary focus of this filing is the press release announcing these results, which was furnished as an exhibit. Investors should note that this information, while important for understanding the company's performance, is furnished and not deemed "filed" for the purposes of certain securities regulations, meaning it doesn't carry the same level of liability implications as a formally filed document. The core of the update is the company's financial performance for the quarter. While the specific figures are detailed in the press release (Exhibit 99), this 8-K serves as the official notification of their release. Investors would look to this filing to understand key financial metrics such as revenue, profitability, and any significant operational updates that may have impacted these results. The press release itself would contain the detailed breakdown of sales by product, geographic region, and any forward-looking statements or guidance provided by management.

Key Highlights

  • 1Biogen Idec Inc. announced its second quarter 2013 financial results via an 8-K filing on July 25, 2013.
  • 2The filing primarily consists of a press release furnishing the company's operational and financial condition for the quarter ended June 30, 2013.
  • 3The press release (Exhibit 99) contains the detailed financial results and is incorporated by reference into the 8-K.
  • 4Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act or subject to its liabilities.
  • 5Investors should refer to the furnished press release for specific financial performance details, including revenue and profitability metrics.
  • 6The filing indicates the availability of exhibits, including the press release, which are crucial for a comprehensive understanding of the results.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Biogen Idec Inc.'s financial and operational results for the second quarter ended June 30, 2013, through a furnished press release.

The detailed financial results, including revenue, profitability, and other key performance indicators, are contained within the press release that is furnished as Exhibit 99 to this 8-K filing. Investors should review this exhibit for specific figures.

No, the press release furnished under Item 2.02 is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the liabilities associated with formally filed documents under that section.

This 8-K filing itself does not detail the specific financial events or updates. Those details are found in the press release (Exhibit 99). Investors would need to consult the press release to understand the company's performance, any significant product updates, or management's outlook for the remainder of the year.